An emerging role of platelet-rich plasma and hyperbaric oxygen in the management of inclusion body myositis: a case report
DOI:
https://doi.org/10.18203/2349-3933.ijam20221361Keywords:
Inclusion body myositis, Hyperbaric oxygen therapy, Hyperbaric oxygenation, Refractory wounds, Regenerative medicine, Platelet-rich plasmaAbstract
Inclusion body myositis is an uncommon inflammatory myopathy that causes progressive muscle weakness. Patient management includes immunosuppressant therapy and nonpharmacologic therapies, like physical, occupational, and speech therapy. Standard treatment plans focus on the maintenance of muscle strength and function. Many patients do not respond to pharmacologic therapies and due to the progressive nature of this myopathy, patients eventually become debilitated. Hyperbaric oxygen therapy and platelet-rich plasma injections were provided as adjunctive therapy to a 70-year-old female patient with inclusion body myositis. After treatment, she had improvement in her muscle function and improved ambulation. This case study highlights the impact of adjunctive therapy in a patient with inclusion body myositis.
References
Dimachkie MM, Barohn RJ. Inclusion body myositis. Neurol clin. 2014;32(3):629-46.
Needham M, Mastaglia FL. Sporadic inclusion body myositis: A review of recent clinical advances and current approaches to diagnosis and treatment. Clin Neurophysiol. 2016;127(3):1764-73.
Rare National Organization for Rare Disorders. Sporadic inclusion body myositis, 2019. Available at: https://rarediseases.org/rare-diseases/sporadic-inclusion-body-myositis. Accessed on 20 December 2021.
Lilleker JB, Rietveld A, Pye SR. On behalf of all UKMYONET contributors, et al. Cytosolic 5′-nucleotidase 1A autoantibody profile and clinical characteristics in inclusion body myositis. Ann Rhem Dis. 2017;76:862-8.
Peng A, Koffman BM, Malley JD, Dalakas MC. Disease progression in sporadic inclusion body myositis: observations in 78 patients. Neurol. 2000;55(2):296-8.
Needham M, Mastaglia FL. Sporadic inclusion body myositis: A review of recent clinical advances and current approaches to diagnosis and treatment. Clin Neurophysiol. 2016;127(3):1764-73.
Naddaf E, Barohn RJ, Dimachkie MM. Inclusion Body Myositis: Update on pathogenesis and Treatment. Neurotherap. 2018;15(4):995-1005.
Morris G, Anderson G, Dean O. The glutathione system: a new drug target in neuroimmune disorders. Mol Neurobiol. 2014;50(3):1059-84.
Jackson CE, Barohn RJ, Gronseth G, Pandya S, Herbelin L. Muscle Study Group. Inclusion body myositis functional rating scale: a reliable and valid measure of disease severity. Mus Ner. 2008;37(4):473-6.
Pell M, Saththasivam P, Stephens PL, Mychaskiw G 2nd. Therapeutic effect of hyperbaric oxygen on inclusion body myositis. Undersea Hyperb Med. 2012;39(6):1111-4.
Sen S, Sen S. Therapeutic effects of hyperbaric oxygen: integrated review. Medical gas research. 2021;11(1):30-3.
Heyboer M, Milovanova TN, Wojcik S, Grant W, Chin M, Hardy KR et al. CD34+/CD45-dim stem cell mobilization by hyperbaric oxygen — Changes with oxygen dosage. Stem Cell Res. 2014;12(3):638-45.
Wu PI, Diaz R, Borg-Stein J. Platelet-rich plasma. Phys Med Rehabil Clin N Am. 2016;27(4):825-53.
Yümün G, Kahaman C, Kahaman N. Effects of hyperbaric oxygen therapy combined with platelet-rich plasma on diabetic wounds: an experimental rat model. Arch Med Sci. 2016;12(6):1370-76.
